Research
Hormonal
Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.
Start with metformin plus either an SGLT-2 inhibitor or a GLP-1 receptor agonist. This combination is proven to protect your heart and kidneys better than older drugs like sulfonylureas. Focus on lifestyle changes like exercise and healthy eating alongside this medication.
StrongSupportsVERY_HIGH confidence
The initial medical treatment should always be a combination treatment with metformin and a sodium-glucose transporter 2 (SGLT-2) inhibitor or a glucagon-like 1 peptide (GLP-1) receptor agonist.
Why this rating
Based on multiple large-scale cardiovascular outcome trials (EMPA-REG, LEADER) cited in the text.
Source
Swiss recommendations of the Society for Endocrinology and Diabetes (SGED/SSED) for the treatment of type 2 diabetes mellitus (2023)
Giacomo Gastaldi et al. · Swiss Medical Weekly · 2023
DOI 10.57187/smw.2023.40060
clinical_guidelineCited 29×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- If initial double combination therapy fails to control HbA1c, a triple combination of metformin, SGLT-2 inhibitor, and GLP-1 receptor agonist is recommended as the best treatment to reduce cardiovascular events and mortality.Good
- Insulin should be the first-line treatment if insulin deficiency is the predominant factor at the onset of type 2 diabetes, followed by cardio-renal protective medications.Good
Related findings · Hormonal
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
- Bariatric surgery (specifically Roux-en-Y gastric bypass and sleeve gastrectomy) consistently achieves sustained weight loss of 25-30% and improves cardiovascular outcomes, serving as the current gold standard for efficacy.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →